Back to results

Dose-escalation Safety and Immunogenicity Study to Compare MTBVAC to BCG in Newborns With a Safety Arm in Adults (MTBVAC-Ph1b)

Primary Purpose

Tuberculosis

Status

Completed

Phase

Phase 1

Locations

South Africa

Study Type

Interventional

Intervention

MTBVAC

BCG

About this trial

This is an interventional prevention trial for Tuberculosis

Eligibility Criteria

1 Day - 50 Years (Child, Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

Adult stage:

Inclusion criteria:

Male or female, age 18 to 50 years
Written informed consent, including permission for access to medical records and an HIV test.
Available for study follow up and display a willingness and capacity to comply to study procedures.
In good general health, as assessed by medical history and a focused physical examination.
HIV test (rapid test, ELISA, or PCR) negative
Quantiferon®-TB Gold (Cellestis) test for latent TB infection negative within 3 weeks of enrolment
BCG vaccination at birth as confirmed by history or the presence of a BCG scar
In the case of female participants, a negative urine or serum pregnancy test at enrolment, not lactating, and willingness to use an acceptable method of contraception to avoid pregnancy for the duration of the study

Infant Stage:

Inclusion Criteria:

Male or female neonates within 96 hours of birth.
Written informed parental consent, including permission to access medical records and results of antenatal HIV tests.
Infant participants and their caregivers available for study follow-up and display the willingness and capacity to comply with study procedures.
Neonates must be in good general health as assessed by antenatal history, delivery records, and focused physical examination.
Birth weight more than or equal to 2500 grams.
Apgar score at 5 minutes more than or equal to 7.
A maternal HIV test result (rapid test, ELISA or PCR) taken during pregnancy must be available, documented and negative.
Estimated gestational age more than or equal to 38 weeks

Exclusion Criteria:

Adult stage Exclusion criteria

A history or evidence of an acute or chronic medical or surgical condition likely to affect the safety, reactogenicity, or immunogenicity of the investigational vaccine
Skin condition, bruising or birth mark at the intended injection site.
History or evidence of previous or current active TB disease
History of a household contact with active TB disease who has received less than 2 months treatment

Infant Stage Exclusion criteria:

Infant must not have received routine BCG vaccination prior to enrolment.
Antenatal, intrapartum, or postnatal medical or surgical condition that may affect the safety, reactogenicity, or immunogenicity of the investigational vaccine.
Maternal HIV test (rapid test, ELISA or PCR) not performed antenatally, HIV test results not available, or HIV test result known positive.
Maternal or other household contact with newly diagnosed or incompletely treated active TB disease.

Sites / Locations

South African Tuberculosis Vaccine Initiative, Brewelskloof Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Active Comparator

Arm Label

MTBVAC Group 1

MTBVAC Group 2

MTBVAC Group 3

BCG Control Group

Arm Description

Intervention: MTBVAC live vaccine (low dose)

Intervention: MTBVAC live vaccine (middle dose)

Intervention: MTBVAC live vaccine (high dose)

Intervention: commercially available BCG live vaccine

Outcomes

Primary Outcome Measures

Safety and reactogenicity in infants and adults: includes injection site and systemic and regional adverse events, solicited and unsolicited. A diary card will be for solicited local, regional, and systemic adverse event data.

Secondary Outcome Measures

Primary immunogenicity analysis (in infants only): Measure of frequencies and co-expression patterns of CD4 and CD8 T cells expressing specific cytokines in whole blood.

Full Information

NCT ID

NCT02729571

First Posted

March 15, 2016

Last Updated

April 30, 2018

Sponsor

Biofabri, S.L

Collaborators

South African Tuberculosis Vaccine Initiative, TuBerculosis Vaccine Initiative, Triclinium Clinical Trial Project Management (Pty) Ltd., Universidad de Zaragoza

1. Study Identification

Unique Protocol Identification Number

NCT02729571

Brief Title

Dose-escalation Safety and Immunogenicity Study to Compare MTBVAC to BCG in Newborns With a Safety Arm in Adults

Acronym

MTBVAC-Ph1b

Official Title

A Randomized, Double-blind, Dose-escalation Clinical Trial of the Safety, Reactogenicity and Immunogenicity of MTBVAC Compared to BCG Vaccine SSI, in Newborns Living in a Tuberculosis Endemic Region With a Safety Arm in Adults

Study Type

Interventional

2. Study Status

Record Verification Date

April 2018

Overall Recruitment Status

Completed

Study Start Date

September 2015 (undefined)

Primary Completion Date

September 2016 (Actual)

Study Completion Date

March 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Biofabri, S.L

Collaborators

South African Tuberculosis Vaccine Initiative, TuBerculosis Vaccine Initiative, Triclinium Clinical Trial Project Management (Pty) Ltd., Universidad de Zaragoza

4. Oversight

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

Randomized, controlled, double blind clinical trial in 2 stages (adult stage, infant stage). The first stage includes 18 HIV uninfected, QFT negative, BCG vaccinated, adult participants, randomized 1:1 to receive BCG Vaccine SSI or MTBVAC at equivalent dose (5x10E05 CFU/0.1mL) (n=9 in each group). Upon favourable safety review by the DSMB for all 18 adults up to day 28 after study vaccination, the second stage will commence in thirty-six (36) HIV unexposed, BCG naïve, newborn infants, randomized 1:3 to receive BCG Vaccine SSI or MTBVAC at one of three different dose levels ( (n=9 in each group).

Detailed Description

Adult Stage: Eighteen (18) adult participants will be recruited and randomized equally into 1 of 2 study groups (n=9 per group): MTBVAC highest dose group (approx. 5x10E05 CFU/0.1mL) or BCG SSI standard human dose (approx. 5x10E05 CFU/0.1mL). Safety assessments will be conducted at D0, D7, D14, D28, D56, D90, and D180 post study vaccination. A diary card will be used to collect solicited local, regional, and systemic adverse event data from D0 through D14. Reactogenicity data will be collected at each study visit. Non-serious adverse events will be collected through D28. Serious adverse events will be collected during the entire study period. Infant Stage: Thirty-six (36) infant participants will be recruited, randomized and allocated into 4 groups of 9 participants: BCG (single dose level 2.5 x 10E05 CFU/0.05 mL); or MTBVAC at three different dose levels (lowest 2.5x10E03 CFU/0.05mL, middle 2.5x10E04 CFU/0.05mL, highest 2.5x10E05 CFU/0.05mL). Vaccination of neonates will be staggered by cohorts on a 3 verum : 1 control basis to allow gradual evaluation of safety and reactogenicity, as follows: Cohort 1: 9 who receive the lowest MTBVAC dose level and 3 BCG control; Cohort 2: 9 who receive the highest MTBVAC dose level and 3 BCG control; Cohort 3: 9 who receive the highest MTBVAC dose level and 3 BCG control. All AEs and biochemical and haematological parameters (safety data) collected up until Day 28 after vaccination of the last subject of each cohort will be reviewed by DSMB to authorize progression to the next group. Safety assessments will be conducted at D0, D7, D14, D28, D70, D90, D180 and D360 post study vaccination. A diary card will be used to collect solicited local, regional, and systemic adverse event data from D0 through D14. Reactogenicity data will be collected at each study visit. Non-serious adverse events will be collected through D28. Serious adverse events will be collected during the entire study period. Unscheduled follow-up face-to-face visits will be performed as needed for safety and adverse event management.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Tuberculosis

7. Study Design

Primary Purpose

Prevention

Study Phase

Phase 1, Phase 2

Interventional Study Model

Parallel Assignment

Masking

ParticipantCare ProviderInvestigatorOutcomes Assessor

Allocation

Randomized

Enrollment

54 (Actual)

8. Arms, Groups, and Interventions

Arm Title

MTBVAC Group 1

Arm Type

Experimental

Arm Description

Intervention: MTBVAC live vaccine (low dose)

Arm Title

MTBVAC Group 2

Arm Type

Experimental

Arm Description

Intervention: MTBVAC live vaccine (middle dose)

Arm Title

MTBVAC Group 3

Arm Type

Experimental

Arm Description

Intervention: MTBVAC live vaccine (high dose)

Arm Title

BCG Control Group

Arm Type

Active Comparator

Arm Description

Intervention: commercially available BCG live vaccine

Intervention Type

Biological

Intervention Name(s)

MTBVAC

Intervention Description

Live-attenuated tuberculosis vaccine

Intervention Type

Biological

Intervention Name(s)

BCG

Intervention Description

Commercially available live-attenuated tuberculosis vaccine

Primary Outcome Measure Information:

Title

Time Frame

Six (6) months post-study vaccination

Secondary Outcome Measure Information:

Title

Primary immunogenicity analysis (in infants only): Measure of frequencies and co-expression patterns of CD4 and CD8 T cells expressing specific cytokines in whole blood.

Time Frame

Six (6) months post-study vaccination

10. Eligibility

Sex

All

Minimum Age & Unit of Time

1 Day

Maximum Age & Unit of Time

50 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Adult stage: Inclusion criteria: Male or female, age 18 to 50 years Written informed consent, including permission for access to medical records and an HIV test. Available for study follow up and display a willingness and capacity to comply to study procedures. In good general health, as assessed by medical history and a focused physical examination. HIV test (rapid test, ELISA, or PCR) negative Quantiferon®-TB Gold (Cellestis) test for latent TB infection negative within 3 weeks of enrolment BCG vaccination at birth as confirmed by history or the presence of a BCG scar In the case of female participants, a negative urine or serum pregnancy test at enrolment, not lactating, and willingness to use an acceptable method of contraception to avoid pregnancy for the duration of the study Infant Stage: Inclusion Criteria: Male or female neonates within 96 hours of birth. Written informed parental consent, including permission to access medical records and results of antenatal HIV tests. Infant participants and their caregivers available for study follow-up and display the willingness and capacity to comply with study procedures. Neonates must be in good general health as assessed by antenatal history, delivery records, and focused physical examination. Birth weight more than or equal to 2500 grams. Apgar score at 5 minutes more than or equal to 7. A maternal HIV test result (rapid test, ELISA or PCR) taken during pregnancy must be available, documented and negative. Estimated gestational age more than or equal to 38 weeks Exclusion Criteria: Adult stage Exclusion criteria A history or evidence of an acute or chronic medical or surgical condition likely to affect the safety, reactogenicity, or immunogenicity of the investigational vaccine Skin condition, bruising or birth mark at the intended injection site. History or evidence of previous or current active TB disease History of a household contact with active TB disease who has received less than 2 months treatment Infant Stage Exclusion criteria: Infant must not have received routine BCG vaccination prior to enrolment. Antenatal, intrapartum, or postnatal medical or surgical condition that may affect the safety, reactogenicity, or immunogenicity of the investigational vaccine. Maternal HIV test (rapid test, ELISA or PCR) not performed antenatally, HIV test results not available, or HIV test result known positive. Maternal or other household contact with newly diagnosed or incompletely treated active TB disease.

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Michele Tameris, MD

Organizational Affiliation

South African Tuberculosis Vaccine Initiative

Official's Role

Principal Investigator

Facility Information:

Facility Name

South African Tuberculosis Vaccine Initiative, Brewelskloof Hospital

City

Worcester

State/Province

Western Cape

ZIP/Postal Code

6850

Country

South Africa

12. IPD Sharing Statement

Plan to Share IPD

Undecided

Citations:

PubMed Identifier

26598141

Citation

Spertini F, Audran R, Chakour R, Karoui O, Steiner-Monard V, Thierry AC, Mayor CE, Rettby N, Jaton K, Vallotton L, Lazor-Blanchet C, Doce J, Puentes E, Marinova D, Aguilo N, Martin C. Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial. Lancet Respir Med. 2015 Dec;3(12):953-62. doi: 10.1016/S2213-2600(15)00435-X. Epub 2015 Nov 17.

Results Reference

background

PubMed Identifier

26786657

Citation

Aguilo N, Uranga S, Marinova D, Monzon M, Badiola J, Martin C. MTBVAC vaccine is safe, immunogenic and confers protective efficacy against Mycobacterium tuberculosis in newborn mice. Tuberculosis (Edinb). 2016 Jan;96:71-4. doi: 10.1016/j.tube.2015.10.010. Epub 2015 Nov 30.

Results Reference

background

PubMed Identifier

23965219

Citation

Arbues A, Aguilo JI, Gonzalo-Asensio J, Marinova D, Uranga S, Puentes E, Fernandez C, Parra A, Cardona PJ, Vilaplana C, Ausina V, Williams A, Clark S, Malaga W, Guilhot C, Gicquel B, Martin C. Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials. Vaccine. 2013 Oct 1;31(42):4867-73. doi: 10.1016/j.vaccine.2013.07.051. Epub 2013 Aug 17.

Results Reference

background

PubMed Identifier

31416768

Citation

Tameris M, Mearns H, Penn-Nicholson A, Gregg Y, Bilek N, Mabwe S, Geldenhuys H, Shenje J, Luabeya AKK, Murillo I, Doce J, Aguilo N, Marinova D, Puentes E, Rodriguez E, Gonzalo-Asensio J, Fritzell B, Thole J, Martin C, Scriba TJ, Hatherill M; MTBVAC Clinical Trial Team. Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial. Lancet Respir Med. 2019 Sep;7(9):757-770. doi: 10.1016/S2213-2600(19)30251-6. Epub 2019 Aug 12.

Results Reference

derived

Learn more about this trial

Dose-escalation Safety and Immunogenicity Study to Compare MTBVAC to BCG in Newborns With a Safety Arm in Adults

We'll reach out to this number within 24 hrs